Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | JAK1 | P23458 | 2/20 | 0.48 |
| ▸ | GRM3 | Q14832 | 3/20 | 0.47 |
| ▸ | PROKR1 | Q8TCW9 | 5/20 | 0.47 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10194852 | 0.87 | KMT2A (0.51) | KMT2AMEN1GRM3PROKR1L3MBTL3 | |
| SCHEMBL17886682 | 0.87 | KMT2A (0.54) | KMT2AMEN1GRM3ALDH1A1 | |
| SCHEMBL21214352 | 0.87 | KMT2A (0.54) | KMT2AMEN1JAK1GRM3L3MBTL3 | |
| SCHEMBL10194851 | 0.83 | GRM3 (0.65) | KMT2AMEN1GRM3PROKR1ALDH1A1 | |
| SCHEMBL10195711 | 0.80 | KDM2B (0.53) | KMT2AMEN1GRM3PROKR1ALDH1A1 | |
| SCHEMBL10194849 | 0.78 | GRM3 (0.53) | KMT2AMEN1GRM3PROKR1ALDH1A1 | |
| SCHEMBL17888330 | 0.76 | KMT2A (0.56) | KMT2AMEN1JAK1L3MBTL3ALDH1A1 | |
| SCHEMBL10195742 | 0.76 | ALDH1A1 (0.54) | KMT2AMEN1GRM3L3MBTL3ALDH1A1 | |
| SCHEMBL10194853 | 0.76 | GRM3 (0.62) | KMT2AMEN1GRM3PROKR1ALDH1A1 | |
| SCHEMBL3456176 | 0.76 | RECQL (0.73) | KMT2AMEN1PROKR1ALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | KMT2A 1797/4885MEN1 2118/4885JAK1 3/4885 |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | KMT2A 1797/4885MEN1 2118/4885JAK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.